Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Holly Williams

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The UK group will pay 124 US dollars a share for Nasdaq-listed Nuvalent (Alamy/PA) -

Pharmaceutical giant GSK has agreed to buy US cancer drug firm Nuvalent in a 10.6 billion US dollar (£8 billion) deal as it looks to expand its cancer treatment offering.

The UK group will pay 124 US dollars (£92.71) a share for Nasdaq-listed Nuvalent, which is based in Cambridge, Massachusetts.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.